安旭生物
(688075)
| 流通市值：11.46亿 | | | 总市值：45.85亿 |
| 流通股本：3177.08万 | | | 总股本：1.27亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 675,427,076.63 | 337,355,385.11 | 724,352,899.92 | 700,584,206.61 |
| 衍生金融资产 | 36,292.62 | 743,982.31 | 699,919.47 | 847,184.66 |
| 应收票据及应收账款 | 224,531,828.24 | 195,900,239.88 | 160,493,158.2 | 150,202,356.69 |
| 其中：应收票据 | 457,437 | - | - | - |
| 应收账款 | 224,074,391.24 | 195,900,239.88 | 160,493,158.2 | 150,202,356.69 |
| 预付款项 | 70,134,517.91 | 62,673,493.95 | 119,345,070.82 | 117,637,194.16 |
| 其他应收款合计 | 15,527,720.54 | 10,297,241.72 | 14,688,267.36 | 15,650,707.46 |
| 存货 | 182,540,923.12 | 197,131,510.4 | 229,531,785.61 | 245,551,776.84 |
| 其他流动资产 | 2,091,572,314.11 | 2,259,528,897.73 | 1,932,733,263.14 | 2,488,795,752.89 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 4,878,653,999.22 | 4,811,722,641.5 | 4,939,056,218.3 | 5,326,362,524.34 |
| 非流动资产: | | | | |
| 固定资产 | 635,880,690.75 | 645,779,850.66 | 483,979,535.39 | 479,772,020.96 |
| 在建工程 | 58,687,203.53 | 47,103,214.42 | 167,821,188.75 | 144,732,594.22 |
| 使用权资产 | 10,281,164.65 | 11,870,006.63 | 35,835,238.25 | 38,085,922.85 |
| 无形资产 | 53,535,903.59 | 54,681,637.24 | 56,096,863.95 | 57,059,894.02 |
| 长期待摊费用 | 15,343,514.77 | 19,832,448.64 | 30,151,538.08 | 30,099,716.78 |
| 递延所得税资产 | 168,202,048.11 | 164,404,018.11 | 140,629,582.84 | 140,629,582.84 |
| 其他非流动资产 | 34,536,698.11 | 34,145,408.37 | 28,313,329.02 | 42,438,664.66 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 976,467,223.51 | 977,816,584.07 | 942,827,276.28 | 932,818,396.33 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,855,121,222.73 | 5,789,539,225.57 | 5,881,883,494.58 | 6,259,180,920.67 |
| 流动负债: | | | | |
| 短期借款 | 1,000,000 | 3,000,000 | 2,000,000 | 2,000,000 |
| 衍生金融负债 | 19,326,137.79 | 14,606,889.77 | 21,110,920.02 | 32,509,038.16 |
| 应付票据及应付账款 | 492,670,220.21 | 475,631,485.62 | 473,973,958.98 | 512,240,961.7 |
| 其中：应付票据 | 75,663,725.92 | 102,481,999.71 | 65,543,500.92 | 32,445,867.52 |
| 应付账款 | 417,006,494.29 | 373,149,485.91 | 408,430,458.06 | 479,795,094.18 |
| 合同负债 | 13,959,406.07 | 13,116,558.23 | 27,574,276.36 | 25,192,157.76 |
| 应付职工薪酬 | 12,141,938.48 | 15,422,344.31 | 10,918,551.55 | 13,264,909.69 |
| 应交税费 | 6,222,722.52 | 4,028,115.45 | 8,033,346.06 | 11,546,316.67 |
| 其他应付款合计 | 18,183,108.29 | 16,715,916.72 | 19,003,324.37 | 359,932,029.44 |
| 应付股利 | - | - | - | 340,400,000 |
| 一年内到期的非流动负债 | 4,410,983.25 | 4,410,983.25 | 9,859,878.42 | 9,859,878.42 |
| 其他流动负债 | 610,957 | 574,068.34 | - | - |
| 流动负债平衡项目 | -0.01 | 0 | 0 | 0 |
| 流动负债合计 | 568,525,473.6 | 547,506,361.69 | 572,474,255.76 | 966,545,291.84 |
| 非流动负债: | | | | |
| 租赁负债 | 5,989,610.78 | 8,171,150.92 | 25,226,772.73 | 27,863,005.04 |
| 预计负债 | 30,851,156.06 | 55,606,812.88 | 70,003,717.72 | 70,452,222 |
| 递延收益 | 3,704,693.82 | 3,704,693.82 | 4,196,841.92 | 4,196,841.92 |
| 递延所得税负债 | 71,159,643.5 | 68,838,267.41 | 58,008,906.16 | 58,008,906.16 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 111,705,104.16 | 136,320,925.03 | 157,436,238.53 | 160,520,975.12 |
| 负债平衡项目 | 0.01 | 0 | 0 | 0 |
| 负债合计 | 680,230,577.77 | 683,827,286.72 | 729,910,494.29 | 1,127,066,266.96 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 127,082,805 | 127,082,805 | 127,082,805 | 127,082,805 |
| 资本公积 | 1,050,333,724.27 | 1,050,333,724.27 | 1,050,333,724.27 | 1,050,333,724.27 |
| 其他综合收益 | 7,890,567.63 | 7,867,155.02 | 8,730,111.86 | 8,733,247.39 |
| 盈余公积 | 51,993,936.35 | 48,584,214.59 | 46,136,497.32 | 46,136,497.32 |
| 未分配利润 | 3,941,885,804.55 | 3,875,597,606.11 | 3,923,331,416.07 | 3,903,266,794.33 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0.01 |
| 归属于母公司股东权益合计 | 5,179,186,837.8 | 5,109,465,504.99 | 5,155,614,554.52 | 5,135,553,068.32 |
| 少数股东权益 | -4,296,192.85 | -3,753,566.14 | -3,641,554.23 | -3,438,414.6 |
| 股东权益平衡项目 | 0.01 | 0 | 0 | -0.01 |
| 股东权益合计 | 5,174,890,644.96 | 5,105,711,938.85 | 5,151,973,000.29 | 5,132,114,653.71 |
| 负债和股东权益合计 | 5,855,121,222.73 | 5,789,539,225.57 | 5,881,883,494.58 | 6,259,180,920.67 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |